Muutke küpsiste eelistusi

Parkinson Disease [Kõva köide]

(, University of Michigan)
  • Formaat: Hardback, 304 pages, kõrgus x laius x paksus: 184x259x24 mm, kaal: 862 g
  • Sari: CONTEMPORARY NEUROLOGY SERIES
  • Ilmumisaeg: 13-Oct-2022
  • Kirjastus: Oxford University Press Inc
  • ISBN-10: 0190843012
  • ISBN-13: 9780190843014
Teised raamatud teemal:
  • Formaat: Hardback, 304 pages, kõrgus x laius x paksus: 184x259x24 mm, kaal: 862 g
  • Sari: CONTEMPORARY NEUROLOGY SERIES
  • Ilmumisaeg: 13-Oct-2022
  • Kirjastus: Oxford University Press Inc
  • ISBN-10: 0190843012
  • ISBN-13: 9780190843014
Teised raamatud teemal:
"Description and discussion of the many aspects of Parkinson disease (PD) is dogged by the fact that PD is an ambiguous concept. What we call PD is an etiologically and clinically heterogeneous meta-syndrome overlapping a number of other disorders. Definitions, diagnostic criteria, and classification schema provide essential common vocabularies for communication among clinicians and researchers. Definitions, diagnostic criteria, and classification schemes for PD, however, are constructs imposed on variable and imperfectly understood disease biology. Difficulties with formulation of PD definitions, diagnostic criteria, and classification schemes include historical and contemporary use of competing definitions of PD, disease heterogeneity, the existence ofdisorders with overlapping clinical and pathological features, and ambiguous use of the terms disease and syndrome. For the purposes of exposition and discussion in this book, an inclusive, perhaps vague, definition of PD is employed:"--

Parkinson Disease is a comprehensive introduction to the biology and clinical features of Parkinson disease (PD). This book is aimed at clinicians in training, general neurologists seeking a useful guide to PD, and scientists seeking an overview of clinical aspects of PD. Topics covered include nosology of PD, PD epidemiology, pathology and pathophysiology of PD, and theories of PD pathogenesis. Clinical features, including the many non-motor features, natural history of disease progression, clinical pharmacology, and management of PD receive coverage. Important themes are heterogeneity of PD, the multi-focal nature of PD pathology, the diversity of clinical features, dopaminergic signaling and the impacts of dopaminergic deficiency, the importance of non-motor features, limitations of existing treatment modalities, and the necessity of approaching PD as a multi-system disorder. The description and discussion of the many aspects of Parkinson disease (PD) is dogged by the fact
that PD is an ambiguous concept. This book intends to be a useful overview, bridging the gap between general textbooks and specific topical reviews.
Preface xi
1 Definition, History, Nosology, and Classification
1(8)
Introduction and Definition
1(1)
Brief History of Pd
2(1)
Nosology and Classification Scheme
3(2)
Classification Level 1: Pism---Division Into Complex Pism and Simple Pism
5(1)
Classification Level 2: Specific Diagnosis Based on Etiology
5(1)
Ambiguities and Future Directions
6(1)
Conclusion
7(2)
2 Epidemiology
9(16)
Introduction
9(2)
Prevalence
11(1)
Incidence
12(1)
Mortality
13(2)
Risk Factors
15(5)
Implications for Understanding Etiopathogenesis and Anticipating the Future Burden of Pd
20(5)
3 Pathology
25(18)
Introduction
25(1)
The Aging Brain
26(1)
Gross Pathology, Lewy Pathology, and α-Synucleinopathy
27(3)
Substantia Nigra Pars Compacta Pathologies
30(2)
Incidental Lewy Body Disease
32(1)
The Braak Et Al. Staging System
33(4)
Synucleinopathy Outside the Brain
37(1)
Non-Synucleinopathy Pathologies
37(6)
4 Pathophysiology I: Basal Ganglia Architecture and the Standard Model
43(18)
Introduction
43(1)
Basic Basal Ganglia Architecture
44(6)
The "Standard" Model of Basal Ganglia Pathophysiology
50(4)
Complexities of Basal Ganglia Architecture
54(4)
Conclusion
58(3)
5 Pathophysiology II: Neurotransmitter Systemdysfunctions
61(16)
Introduction
61(1)
Nigrostriatal Dopamine Signaling Functions
61(5)
Habit Formation and Chunking
66(1)
Cholinergic Projection System Dysfunctions
67(4)
Serotoninergic System Dysfunctions
71(1)
Conclusion and Future Challenges
72(5)
6 Genetics of Parkinson Disease
77(16)
Introduction
77(2)
Dominant Forms of Pd
79(4)
Recessive Forms of Pd
83(2)
Glucocerebrosidase (Gba)
85(2)
Pd Genetic Risk Factors
87(1)
Implications of Pd Genetic Research
88(5)
7 Pathogenesis
93(32)
Neuronal Vulnerability
93(4)
Α-Synuclein
97(2)
The Prion-Like Hypothesis
99(3)
Mitochondrial Dysfunction
102(2)
Oxidative Stress
104(4)
Endolysosomal Dysfunction
108(5)
Neuroinflammation
113(2)
Neuroprotection Trials
115(3)
Conclusion
118(7)
8 Prodromal Parkinson Disease
125(12)
Introduction
125(2)
Rem Sleep Behavior Disorder
127(2)
Observational Studies
129(1)
Rem Sleep Behavior Disorder Cohort Studies
130(2)
Genetic Cohort Studies
132(1)
Pure Autonomic Failure
133(1)
Conclusion
133(4)
9 Clinical Features I: Initial Evaluation
137(28)
Presentation Features
137(4)
Nature of Diagnosis and Diagnostic Criteria
141(3)
History
144(3)
Examination
147(3)
Differential Diagnosis
150(9)
Treatment Responsiveness
159(1)
Diagnostic Accuracy
160(5)
10 Clinical Features II: Non-Motor Features
165(28)
Introduction
165(2)
Cognitive Impairments
167(6)
Neuropsychiatry Disorders
173(6)
Sleep Disorders and Excessive Daytime Somnolence
179(3)
Pain and Akathisia
182(2)
Fatigue
184(1)
Autonomic Disorders
185(3)
Visual Disorders
188(1)
Oral Health
188(1)
Conclusion
188(5)
11 Clinical Features III: Natural History
193(30)
Introduction
193(1)
Assessing Pd Progression
194(6)
Pd Progression: Clinically Salient Features
200(6)
Subgroups
206(2)
Natural History
Summary
208(3)
Continuing Care
211(7)
End-Of-Life Care
218(5)
12 Pharmacology I: L-Dopa Pharmacokinetics and Pharmacodynamics
223(14)
Introduction
223(1)
Dopaminergic Neurotransmission
224(2)
L-Dopa Pharmacokinetics
226(2)
L-Dopa Pharmacodynamics
228(4)
Peak Dose Dyskinesias
232(1)
Interactions of L-Dopa: Pharmacokinetics, Pharmacodynamics, and Disease Progression
233(1)
Conclusion and Future Directions
234(3)
13 Pharmacology II: Treating Parkinson Disease
237(24)
Introduction
237(1)
Using L-Dopa
238(4)
When the Honeymoon Is Over
242(5)
L-Dopa Adjuncts
247(3)
Dopamine Agonists
250(3)
Cholinergic Agents
253(1)
Other Symptomatic Therapies
254(2)
Future Directions
256(5)
14 Surgery
261(20)
Introduction
261(1)
Deep Brain Stimulation: Rationale and Possible Mechanisms
262(2)
Deep Brain Stimulation: Indications
264(3)
Deep Brain Stimulation: Procedures
267(1)
Deep Brain Stimulation: Stn Dbs Benefits
268(2)
Deep Brain Stimulation: Gpi Dbs Benefits and Stn Versus Gpi Dbs
270(1)
Deep Brain Stimulation: Adverse Events
271(1)
Lesional Procedures
272(1)
Cell-Based and Gene Therapies
272(2)
Future Directions
274(3)
Coda: Looking Ahead
277(1)
Disease Heterogeneity
277(1)
Epidemiology
277(1)
Treatments
278(1)
Basic and Clinical Research Synergies
279(2)
Index 281
Roger L. Albin, M.D. is a graduate of Oberlin College and the University of Pittsburgh School of Medicine. He received clinical and post-doctoral training at the University of Michigan, where his mentors were Anne Young and the late Jack Penney. His primary research interest is the pathophysiology of basal ganglia disorders, including Parkinson disease, Tourette syndrome, and Huntington disease. He is presently Co-Director of the Parkinson Disease & Movement Disorders Division and Director of the Udall Center at the University of Michigan, and Associate Director for Research at the VAAAHS GRECC.